Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

In the long-run, an orchiectomy is much cheaper than LHRH agonists." Unfortunately, understanding the details of hormone therapy for prostate cancer can be difficult. Which drug or combination of ...

“Prostate cancer feeds on testosterone,” explains ... ADT includes medications that affect the production of LHRH: LHRH agonists and LHRH antagonists. 2. LHRH agonists and LHRH antagonists ...

When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

Transdermal estradiol monotherapy costs approximately one-tenth the price of LHRH agonist therapy alone, and the disparity increases further when compared with LHRH and NSAA combination therapy ...

A total of 542 patients had received prior HT, predominantly LHRH agonists (53.7 %); of these, 455 had received prior LHRH analogue therapy (LHRH agonists or GnRH antagonists). Baseline PSA (media ...

Hormone therapy can make a big difference for men with recurrent or metastatic prostate cancer. But it isn't a cure. Its effects are limited and the side effects can be difficult to cope with.

LHRH-agonists in Early Breast Cancer Overview group (2007) Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive ...

antagonist which holds a European marketing authorisation for the treatment of adult male patients with advanced hormone-dependent prostate cancer. Compared with its main comparators, the LHRH ...

an LHRH agonist, and relugolix in time to castration resistant-prostate cancer, a near uniformly lethal form of the disease. Furthermore, the safety profile of relugolix was commendably consistent ...

As over half of all early-stage breast cancers remain estrogen-receptor-positive, the goal of adjuvant hormone therapy is to reduce the local concentrations of estrogen. Sharma and colleagues ...

Caption Lymph node and osseous metastatic, castration-resistant, and chemotherapy-naive prostate cancer (status post androgen-deprivation therapy using LHRH analogs and Bicalutamide) in a 62-year ...